Bazhen Tablets Veterinary Grade API is released as a crystalline, non-sterile active substance intended for downstream manufacture of tablets, injections, capsules, powders, granules, premixes, and solutions. The manufacturer’s coding for this multi-dosage-form grade is BZ-VT-API-MD. The material is not a formulated premix, medicated feed article, or ready-to-use injection; it contains no preservative, binder, or carrier system. The release profile is aligned with USP, Ph. Eur., and relevant veterinary monograph methods, and the certificate of analysis reports assay, related substances, residual solvents, water content, particle-size distribution, and elemental impurities. Terminal sterilization, formulation, and process validation remain the responsibility of the downstream manufacturer. Published data for this exact product designation are limited; the following processing ranges are derived from the manufacturer’s technical bulletin and compendial alignment.

What Limits Direct Compressibility in Low-Dose Tablet and Capsule Formulations?

The solid-dosage-form grade is controlled to a d90 of ≤ 125 µm and a d50 of 35–55 µm by laser diffraction, with a span value below 1.8. Bulk and tapped density limits of 0.42–0.58 g/mL and 0.55–0.72 g/mL are established according to USP <616> and Ph. Eur. 2.9.34. The corresponding Carr index is maintained below 25% and Hausner ratio below 1.25 when tested according to Ph. Eur. 2.9.36. A narrow particle-size window is required because low-dose formulations containing ≤ 2.0% active ingredient exhibit segregation on direct compression lines when the API median particle size drifts more than 15 µm from the excipient blend.

On a rotary tablet press with maximum main compression force of 25 kN and turret speed of 30 RPM, ejection force remains below 1.8 kN when granule moisture is held at 2.0–3.5%. Capping is not observed at tablet hardness 60–80 N for flat-faced bevel-edge tooling of 8 mm diameter. Direct compression is restricted to formulations with active content above 10 mg per tablet; below that threshold, content uniformity requires wet granulation or ordered mixing because dry blending for more than 30 min has produced top-to-bottom assay drift of 8–12% relative standard deviation in stratified sampling.

The crystalline form is confirmed by XRPD according to USP <941>. Storage below 25°C and 60% RH is specified to avoid hydrate conversion, which alters dissolution and compressibility. Dissolution testing according to USP <711> or Ph. Eur. 2.9.3 in 900 mL buffer at pH 4.5 and 50 RPM basket speed applies an immediate-release acceptance criterion of not less than 80% released in 30 min for tablets and capsules. Published data for this specific dissolution configuration remains limited and should be verified during formulation development.

When the Same API Lot Is Split Across Capsules, Powders, Granules, and Soluble Premixes

Cross-dosage-form use requires that the API remain chemically stable in the presence of excipients with differing water activity. Capsule blending with lactose monohydrate and sodium starch glycolate at 25°C and 60% RH for 12 weeks showed no individual related substance exceeding 0.10% and total related substances remaining below 0.50% by HPLC at 230 nm. The same organic impurity limits apply to powder sachets and granules. Blend uniformity is assessed by stratified sampling of an IBC bin blender at 10 sampling locations. A relative standard deviation of ≤ 5.0% is retained after 20 min blending at 12 RPM with a 60% vessel fill.

Capsule filling on a dosator-type machine with size 3 capsules and target fill weight 180 mg requires the granule fraction below 45 µm to remain below 20% to avoid fill weight drift. Powder sachets require the same particle-size control because excess fines increase dusting and adhesion to sealing jaws. For premix applications, the API is mixed with calcium carbonate or rice hull carriers at inclusion rates of 0.5–5.0%. Segregation is minimized when the median particle size of the API is matched to the carrier within ± 20 µm. At carrier moisture above 12%, the API may adhere to carrier surfaces and produce assay non-uniformity. Milling the premix through a 0.8 mm screen after blending re-distributes the active; however, milling above 1,200 RPM can generate fines and compromise flow.

Parenteral-grade use adds bacterial endotoxin control. Because the API is non-sterile, the downstream producer must apply terminal sterilization or aseptic processing. The release specification limits bacterial endotoxins to ≤ 0.50 EU/mg by USP <85> or Ph. Eur. 2.6.14. Reconstitution at 10 mg/mL in water for injection at 25°C, followed by pH adjustment with 0.1 M hydrochloric acid to pH 3.0–4.0, yields a clear solution filtered through a 0.22 µm PVDF membrane. Filtration adsorptive loss is controlled by pre-rinsing the membrane with 0.9% sodium chloride. Particulate matter in the finished injection is tested according to USP <788> or Ph. Eur. 2.9.19; limits depend on container volume. Terminal sterilization at 121°C for 15 min may be acceptable only after pH and oxygen sensitivity studies; the API should not be autoclaved in alkaline solution because degradation increases.

Residual Solvent and Related Substance Limits Under Multi-Market Veterinary Filings

Residual solvents are controlled by USP <467> and Ph. Eur. 2.4.24. Class 1 solvents are not detected at a limit of 1 ppm. Class 2 solvent limits follow ICH Q3C: methanol ≤ 3,000 ppm, dichloromethane ≤ 600 ppm, and toluene ≤ 890 ppm. Class 3 solvents are controlled as total residual not more than 0.5% by loss on drying and gas chromatography. Packaging in double low-density polyethylene bags inside a fiber drum is specified; the packaging does not introduce volatile contaminants.

Related substances are determined by gradient reversed-phase HPLC on a C18 column maintained at 40°C. The method uses UV detection at 230 nm. An unspecified impurity is limited to ≤ 0.10%; total impurities are ≤ 0.50%. The reporting threshold is 0.05%. This profile distinguishes the product from feed-grade substances that may not be tested for organic impurities at these levels. Elemental impurities follow ICH Q3D; cadmium, lead, arsenic, and mercury are controlled by USP <232>/<233> or equivalent. Limits are route-dependent; the parenteral route applies the lower parenteral concentration limits. The API is not assessed as a substitute for a finished product risk assessment.

Moisture-Sensitive Granulation and Drying Runs Within a Narrow Product-Temperature Range

Wet granulation in a high-shear mixer with 250 L bowl capacity uses purified water or a 5.0% povidone K30 binder solution at 18–22% of dry blend weight. The endpoint is controlled by torque increase of 2.5–4.0 N·m rather than time. Over-granulation above 4.5 N·m produces dense agglomerates that require milling and increase fines below 45 µm after dry sizing. The wet mass is discharged through a 4.0 mm screen and dried in a fluid-bed dryer.

Fluid-bed drying uses inlet air at 60–65°C and product temperature 38–42°C. Loss on drying endpoint is 2.0–3.5% according to USP <921> / Ph. Eur. 2.5.12. Product temperature above 50°C during the terminal phase increases the fines fraction below 45 µm by approximately 15–20% and can alter the crystalline habit. Drying below 2.0% moisture causes electrostatic charging in the compression blend. The use of near-infrared moisture monitoring is recommended to stop the dryer at the water activity corresponding to 2.5% water rather than on a fixed time basis.

Scale-up from 25 kg to 250 kg batch size shows that the wet mass torque endpoint shifts by 0.5–1.0 N·m per 100 kg scale because of bowl temperature and blade tip speed differences. The impeller tip speed should be maintained at 4.0–5.0 m/s across scales to preserve granule size distribution. Transfer should be completed within 15 min to avoid moisture migration. These ranges are equipment-specific; revalidation is required if the granulator blade geometry or dryer air distribution differs.

Compared with a single-tablet-grade API, the product differs in that the same lot is released against endotoxin and particulate controls applicable to parenteral use while retaining particle-size limits suitable for low-dose solid dosage forms. Compared with feed-grade active substances, the product adds residual solvent, related substance, and elemental impurity testing rather than only assay and moisture. Compared with a formulated premix, the API contains no carrier and is used at defined inclusion rates. No preservative or stabilizer system is present; each finished dosage form must be developed and validated under the relevant veterinary marketing authorization dossier.